MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

GlycoMimetics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

0.26 13.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.22

Max

0.27

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2.6M

-7.2M

Pelnas, tenkantis vienai akcijai

-0.112

Darbuotojai

4

EBITDA

399K

-5.3M

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

14M

Ankstesnė atidarymo kaina

-12.78

Ankstesnė uždarymo kaina

0.26

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

GlycoMimetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-07-25 15:11; UTC

Pagrindinės rinkos jėgos

GlycoMimetics Shares Drop 27% After Restructuring Plan, Job Cuts

Akcijų palyginimas

Kainos pokytis

GlycoMimetics Inc Prognozė

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.223 / 0.2743Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.